GlassScriptPhysician profile
Vadim Azbel
NPI 1538187695
$11,893.62
in general payments reported to CMS, 2019-2025
19 companies · $1,128 in 2025
The $1,128 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,513 · 2020: $159 · 2021: $230 · 2022: $541 · 2023: $560 · 2024: $763 · 2025: $1,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,437 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,437.49 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $7,470.43 | 2019 | |
| Abbvie INC. | $647.21 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $450.10 | 2019-2025 | Fanapt |
| Alkermes, INC. | $393.96 | 2019-2025 | Lybalvi |
| Almatica Pharma LLC | $370.32 | 2021-2025 | Loreev Xr, Gralise |
| Sunovion Pharmaceuticals INC. | $317.76 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $312.20 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $300.67 | 2019-2025 | Rexulti |
| Lundbeck LLC | $250.66 | 2019-2025 | Rexulti, Brintellix, Abilify Maintena |
| Neurocrine Biosciences, INC. | $250.04 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $228.88 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $226.99 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $202.00 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $176.67 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $103.21 | 2021-2025 | Cobenfy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $78.18 | 2019 | |
| Bausch Health US, LLC | $55.05 | 2024-2025 | Aplenzin |
| Idorsia Pharmaceuticals US INC | $34.29 | 2022 | |
| Glaxosmithkline, LLC. | $25.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vadim Azbel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.